What is the recommended management for non‑alcoholic fatty liver disease?

Treatment for Fatty Liver (NAFLD)

Lifestyle modification with targeted weight loss of 7-10% through caloric restriction and exercise is the cornerstone of NAFLD treatment, with no pharmacotherapy recommended for patients without steatohepatitis or fibrosis. 1

Risk Stratification Determines Treatment Intensity

The first critical step is determining disease severity, as treatment should be limited to those with NASH (nonalcoholic steatohepatitis) or significant fibrosis 2, 3. Patients with simple steatosis have excellent prognosis and require only lifestyle counseling, not pharmacotherapy 1.

For ALL NAFLD Patients (Regardless of Severity):

Weight Loss Target:

• 3-5% body weight loss improves steatosis
• 7-10% weight loss is required to improve necroinflammation and achieve histological improvement 2, 1
• Weight loss >10% shows the strongest dose-response relationship with NASH resolution and fibrosis improvement 4

Dietary Approach:

• Follow Mediterranean diet pattern - this has the strongest evidence for reducing liver fat compared to low-fat/high-carbohydrate diets 5, 1
• Create 500-1000 kcal daily deficit to achieve 0.5-1 kg weight loss per week 1
• Eliminate fructose-containing beverages and processed foods 5, 1
• Replace saturated fats with PUFAs (especially omega-3) and MUFAs 5
• Increase fiber through whole grains, vegetables, fruits, legumes, nuts, and seeds 5

Exercise Prescription:

• 150-200 minutes per week of moderate-intensity aerobic exercise (brisk walking, stationary cycling) spread over 3-5 sessions 1, 6
• Resistance training on at least 2 days per week 6
• Exercise alone reduces hepatic steatosis even without significant weight loss 2, 3

Alcohol Limits:

• Keep below risk threshold: <30g/day for men, <20g/day for women 1
• Complete abstinence is mandatory for NASH-cirrhosis to reduce HCC risk 1

Coffee: No restrictions - protective effect demonstrated 1

For Patients with NASH or Significant Fibrosis:

Pharmacotherapy Considerations:

Metformin: NOT RECOMMENDED

• Has no significant effect on liver histology and should not be used as specific treatment for NASH 2, 3
• Despite improving aminotransferases, multiple trials show no histological benefit 1

Pioglitazone:

• Improves histological features in non-diabetic NASH patients (except fibrosis) 1
• Can be considered in select patients with biopsy-proven NASH 7, 8

Vitamin E:

• 800 IU/day improved steatohepatitis in non-diabetic patients with biopsy-proven NASH 4
• Long-term safety concerns limit widespread use 5

GLP-1 Receptor Agonists (e.g., Liraglutide, Dulaglutide):

• Liraglutide 1.8mg daily achieved 39% NASH resolution vs 9% placebo in trials 1
• Should be prioritized in patients with concurrent type 2 diabetes 4, 9

SGLT2 Inhibitors:

• Beneficial for cardiometabolic profile and can reverse steatosis in diabetic patients 4
• Use based on diabetes guidelines when T2DM present 4

When to Refer to Hepatology:

Patients with:

• FIB-4 score >2.67
• Liver stiffness measurement >12.0 kPa on transient elastography
• Biopsy-proven clinically significant fibrosis
• Need for HCC surveillance (cirrhosis) 4

Critical Pitfalls to Avoid:

1. Do not prescribe metformin specifically for liver disease - it has proven ineffective for histological improvement despite biochemical changes 2, 3

2. Do not use pharmacotherapy in simple steatosis without NASH/fibrosis - these patients have excellent prognosis and only need lifestyle modification 1

3. Do not recommend rapid weight loss - gradual weight reduction (0.5-1 kg/week) is essential for sustained benefit 1

4. Do not overlook cardiovascular risk management - statins are safe and recommended; NAFLD patients have increased CVD mortality 6, 4

5. Do not forget diabetes screening - annual HbA1c testing recommended as NAFLD patients are high-risk for T2DM 6

Practical Implementation Algorithm:

1. Assess disease severity (FIB-4, imaging, consider biopsy if indicated)
2. If simple steatosis: Lifestyle counseling only - Mediterranean diet, 150-200 min/week exercise, 7-10% weight loss target
3. If NASH or significant fibrosis: Intensive lifestyle intervention PLUS consider pharmacotherapy (pioglitazone, vitamin E, or GLP-1RA if diabetic)
4. If advanced fibrosis/cirrhosis: Refer to hepatology for multidisciplinary management and HCC surveillance
5. All patients: Manage cardiovascular risk factors aggressively (statins, antihypertensives as indicated)

The evidence consistently shows that structured weight loss programs are more successful than office-based counseling alone 4, so formal referral to weight management services should be considered when targets are not met 6. Bariatric surgery is an option for appropriate candidates with obesity and significant fibrosis 4.